UPDATE - Oppenheimer Initiates Coverage on Coronado Biosciences (CNDO) with an Outperform; Harnessing Nature to Treat Disease and Cancer

February 24, 2012 9:12 AM EST Send to a Friend
Get Alerts CNDO Hot Sheet
Price: $1.70 -5.56%

Rating Summary:
    2 Buy, 5 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 27 | Down: 26 | New: 17
Trade CNDO Now!
Join SI Premium – FREE
UPDATE - Oppenheimer initiates coverage on Coronado Biosciences (NASDAQ: CNDO) with an Outperform. PT $12.00.

Oppenheimer analyst said, "Coronado's leading asset (CNDO-201) is a pharmaceutical formulation of porcine parasite for the treatment of human autoimmune disease. Although the therapy is unconventional, it aims to recreate a natural relationship that humans have had with intestinal parasites throughout the millenia until the significant public health changes in the last century. The treatment showed encouraging efficacy in Crohn's disease and ulcerative colitis, as well as early data in multiple sclerosis. We believe that the market is largely overlooking Coronado due to the unconventional approach of its leading asset. We anticipate investors to discover this company, particularly as new CNDO-201 data is presented in 2H12."

To see more ratings on CNDO, Click Here


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

New Coverage

Add Your Comment